journal
https://read.qxmd.com/read/38724277/relationship-between-absorbed-dose-and-response-in-neuroendocrine-tumors-treated-with-177-lu-lu-dotatate
#21
JOURNAL ARTICLE
Carl Fredrik Warfvinge, Johan Gustafsson, Daniel Roth, Jan Tennvall, Johanna Svensson, Peter Bernhardt, Anna Åkesson, Elinore Wieslander, Anna Sundlöv, Katarina Sjögreen Gleisner
Peptide receptor radionuclide therapy presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the details of how neuroendocrine tumors (NETs) respond to different absorbed doses are insufficiently known. Here, we investigated the relationship between tumor-absorbed dose and tumor response in a cohort of patients with NETs treated with [177 Lu]Lu-DOTATATE. Methods: This was a retrospective study based on 69 tumors in 32 patients treated within a clinical trial...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38724276/diagnostic-performance-of-18-f-alf-thretide-pet-ct-in-patients-with-newly-diagnosed-prostate-cancer-using-histopathology-as-reference-standard
#22
JOURNAL ARTICLE
Jie Zang, Yun Yang, Shaoming Chen, Chao Wang, Shaohao Chen, Shun Hu, Hai Cai, Xiaodong Li, Ning Xu, Xiaoyuan Chen, Jingjing Zhang, Weibing Miao
This study aimed to assess the diagnostic value of [18 F]AlF-thretide PET/CT in patients with newly diagnosed prostate cancer (PCa). Methods: In total, 49 patients with biopsy-proven PCa were enrolled in this prospective study. All patients underwent [18 F]AlF-thretide PET/CT, and the scoring system of the PRIMARY trial was used for PET image analysis. The dosimetry evaluation of [18 F]AlF-thretide was performed on 3 patients. Pathologic examination was used as the reference standard to evaluate the location, number, size, and Gleason score of tumors, for comparison with the [18 F]AlF-thretide PET/CT results...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38724275/determining-hemodynamically-significant-coronary-artery-disease-patient-specific-cutoffs-in-quantitative-myocardial-blood-flow-using-15-o-h-2-o-pet-imaging
#23
JOURNAL ARTICLE
Roel Hoek, Pepijn A van Diemen, Pieter G Raijmakers, Roel S Driessen, Yvemarie B O Somsen, Ruben W de Winter, Ruurt A Jukema, Jos W R Twisk, Lourens F H J Robbers, Pim van der Harst, Antti Saraste, Mark Lubberink, Jens Sörensen, Paul Knaapen, Juhani Knuuti, Ibrahim Danad
Currently, cutoffs of quantitative [15 O]H2 O PET to detect fractional flow reserve (FFR)-defined coronary artery disease (CAD) were derived from a single cohort that included patients without prior CAD. However, prior CAD, sex, and age can influence myocardial blood flow (MBF). Therefore, the present study determined the influence of prior CAD, sex, and age on optimal cutoffs of hyperemic MBF (hMBF) and coronary flow reserve (CFR) and evaluated whether cutoff optimization enhanced diagnostic performance of quantitative [15 O]H2 O PET against an FFR reference standard...
May 9, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38697673/reply-artificial-intelligence-algorithms-are-not-clairvoyant
#24
LETTER
Joyita Dutta, Vibha Balaji, Tzu-An Song
No abstract text is available yet for this article.
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38697672/-68-ga-fap-2286-pet-of-solid-tumors-biodistribution-dosimetry-and-comparison-with-18-f-fdg
#25
JOURNAL ARTICLE
Brad Kline, Surekha Yadav, Youngho Seo, Robin Cumming Ippisch, Jessa Castillo, Rahul R Aggarwal, Robin Kate Kelley, Spencer C Behr, Robert R Flavell, Courtney Lawhn-Heath, Michelle Melisko, Hope S Rugo, Victoria Wang, Sue S Yom, Patrick Ha, Fei Jiang, Thomas A Hope
Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety of cancers, has become a target of novel PET tracers. The purpose of this report is to evaluate the imaging characteristics of 68 Ga-FAP-2286, present the first-to our knowledge-dosimetry analysis to date, and compare the agent with 18 F-FDG and FAPI compounds. Methods: Patients were administered 219 ± 43 MBq of 68 Ga-FAP-2286 and scanned after 60 min. Uptake was measured in up to 5 lesions per patient and within the kidneys, spleen, liver, and mediastinum (blood pool)...
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38697671/cerebral-18-f-fdg-pet-ct-metabolism-as-diagnostic-signature-for-central-nervous-system-toxicity-after-immune-checkpoint-blockade-cancer-treatment
#26
JOURNAL ARTICLE
Yifei Ma, Jiling Zeng, Fadian Ding, Yiwei Xu, Youlong Wang, Guanqing Zhong, Nianqi Liu, Yanqi Wang, Yiming Li, Shuqin Chen, Xiaolong Wei, Pengfei Zhu, Guangmin Jian, Yu Si Niu, Guangzhen Fu, Cantong Liu, Guiqiang Li, Xiaotong Zhou, Ao Zhang, Shangeng Weng
Our aim was to investigate probable biomarkers specific to immune-related central nervous system toxicity (CNST) in cancer patients treated with immune checkpoint inhibitors (ICI) by analysis of 18 F-FDG PET/CT images. Methods: Cancer patients receiving ICI treatment were enrolled in a multicenter observational study that analyzed regional metabolic changes before and during CNST onset from January 2020 to February 2022. In 1:1 propensity score-matched pairs, the regional SUVmean of each bilateral brain lobe of CNST patients (CNST+) was compared with that of patients who had central nervous system infections (CNSIs) and patients without CNST or CNSI (CNST-)...
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38697670/artificial-intelligence-algorithms-are-not-clairvoyant
#27
LETTER
Bradley J Beattie
No abstract text is available yet for this article.
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38697669/safety-and-efficacy-of-extended-therapy-with-177-lu-lu-psma-a-german-multicenter-study
#28
JOURNAL ARTICLE
Robert Seifert, Tugce Telli, Constantin Lapa, Mélanie Desaulniers, Turkay Hekimsoy, Wolfgang A Weber, Christian Pfob, Boris Hadaschik, Martin Bögemann, Michael Schäfers, Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Wolfgang P Fendler
Prospective results have demonstrated favorable safety and efficacy of [177 Lu]Lu-PSMA radiopharmaceutical therapy for up to 6 cycles in men with metastatic castration-resistant prostate cancer. However, no systematic data are available outlining the feasibility of extended therapy beyond 6 cycles. We aim to evaluate the safety and efficacy of extended [177 Lu]Lu-PSMA radiopharmaceutical therapy in patients who have received more than 6 cycles. Methods: In total, 111 patients were included in this multicenter retrospective analysis...
May 2, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664020/mri-and-18-f-fet-pet-for-multimodal-treatment-monitoring-in-patients-with-brain-metastases-a-cost-effectiveness-analysis
#29
JOURNAL ARTICLE
Jurij Rosen, Jan-Michael Werner, Garry S Ceccon, Elena K Rosen, Michael M Wollring, Isabelle Stetter, Philipp Lohmann, Felix M Mottaghy, Gereon R Fink, Karl-Josef Langen, Norbert Galldiks
PET using the radiolabeled amino acid O -(2-[18 F]fluoroethyl)-l-tyrosine (18 F-FET) has been shown to be of value for treatment monitoring in patients with brain metastases after multimodal therapy, especially in clinical situations with equivocal MRI findings. As medical procedures must be justified socioeconomically, we determined the effectiveness and cost-effectiveness of 18 F-FET PET for treatment monitoring of multimodal therapy, including checkpoint inhibitors, targeted therapies, radiotherapy, and combinations thereof in patients with brain metastases secondary to melanoma or non-small cell lung cancer...
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664019/randomized-trial-of-prostate-specific-membrane-antigen-pet-ct-before-definitive-radiotherapy-for-unfavorable-intermediate-and-high-risk-prostate-cancer-psma-drt-trial
#30
JOURNAL ARTICLE
John Nikitas, Ethan Lam, Kiara Adame Booker, Wolfgang P Fendler, Matthias Eiber, Boris Hadaschik, Ken Herrmann, Nader Hirmas, Helena Lanzafame, Martin Stuschke, Johannes Czernin, Michael L Steinberg, Nicholas G Nickols, Amar U Kishan, Jeremie Calais
This multicenter randomized phase III trial (NCT04457245) evaluated the effect of performing prostate-specific membrane antigen (PSMA) PET/CT before definitive radiotherapy. Methods: Men with unfavorable intermediate- or high-risk prostate cancer were randomized 1.08:1 between receiving and not receiving a PSMA PET/CT scan before definitive radiotherapy. All other imaging modalities were allowed in the control arm. The primary endpoint was 5-y progression-free survival. Results: Fifty-four men were randomized between November 2020 and December 2021 (PSMA PET/CT, n = 25; control, n = 29)...
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664018/-68-ga-ga-fapi-46-false-positive-uptake-after-chemotherapy-in-nonseminomatous-germ-cell-tumor-metastatic-lesions
#31
JOURNAL ARTICLE
Vinicius Ludwig, Peter George Maliha, John Shen, David Tonnelet, Steve Raman, Mark S Litwin, Jeremie Calais
No abstract text is available yet for this article.
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664017/dose-reduction-in-pediatric-oncology-patients-with-delayed-total-body-18-f-fdg-pet-ct
#32
JOURNAL ARTICLE
Clemens Mingels, Benjamin A Spencer, Hande Nalbant, Negar Omidvari, Mehrad Rokni, Axel Rominger, Fatma Sen, Simon R Cherry, Ramsey D Badawi, Yasser G Abdelhafez, Lorenzo Nardo
Our aim was to define a lower limit of reduced injected activity in delayed [18 F]FDG total-body (TB) PET/CT in pediatric oncology patients. Methods: In this single-center prospective study, children were scanned for 20 min with TB PET/CT, 120 min after intravenous administration of a 4.07 ± 0.49 MBq/kg dose of [18 F]FDG. Five randomly subsampled low-count reconstructions were generated using ¼, ⅛, [Formula: see text], and [Formula: see text] of the counts in the full-dose list-mode reference standard acquisition (20 min), to simulate dose reduction...
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664016/prospective-comparison-of-68-ga-neob-and-68-ga-psma-r2-pet-mri-in-patients-with-biochemically-recurrent-prostate-cancer
#33
JOURNAL ARTICLE
Heying Duan, Hong Song, Guido A Davidzon, Farshad Moradi, Tie Liang, Andreas Loening, Shreyas Vasanawala, Andrei Iagaru
Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptors are both overexpressed in prostate cancer (PC) but may provide complementary information.68 Ga-PSMA-R2 and 68 Ga-NeoB (DOTA- p -aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His-NH-CH[CH2 -CH(CH3 )2 ]2 ) are novel PET radiopharmaceuticals that were developed for theranostic use. In this phase II imaging study, we assessed the feasibility, safety, and diagnostic performance of 68 Ga-NeoB and 68 Ga-PSMA-R2 PET/MRI for detection of biochemically recurrent PC...
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664015/evaluation-of-neurodegenerative-disorders-with-amyloid-%C3%AE-tau-and-dopaminergic-pet-imaging-interpretation-pitfalls
#34
JOURNAL ARTICLE
Brian J Burkett, Derek R Johnson, Val J Lowe
Antiamyloid therapies for Alzheimer disease recently entered clinical practice, making imaging biomarkers for Alzheimer disease even more relevant to guiding patient management. Amyloid and tau PET are valuable tools that can provide objective evidence of Alzheimer pathophysiology in living patients and will increasingly be used to complement 18 F-FDG PET in the diagnostic evaluation of cognitive impairment and dementia. Parkinsonian syndromes, also common causes of dementia, can likewise be evaluated with a PET imaging biomarker,18 F-DOPA, allowing in vivo assessment of the presynaptic dopaminergic neurons...
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38664014/frequent-amplification-and-overexpression-of-psma-in-basallike-breast-cancer-from-analysis-of-the-cancer-genome-atlas
#35
JOURNAL ARTICLE
Wenhui Zhou, Sumit Halder, Sanna Herwald, Michael Ghijsen, Gowhar Shafi, Mohan Uttarwar, Eric Rosen, Benjamin Franc, Sirish Kishore
Prostate-specific membrane antigen (PSMA) is frequently overexpressed in nonprostate malignancies. This preclinical study investigated the molecular basis of the application of PMSA-targeting radiopharmaceuticals in breast cancer subtypes. Methods: The somatic copy number status and the transcriptomic and protein expressions of FOLH1 (gene name of PSMA) were analyzed across breast cancer subtypes in 998 patients from The Cancer Genome Atlas dataset. Results: FOLH1 was frequently amplified in basallike breast cancer (BLBC) (32%) compared with luminal and human epidermal growth factor receptor 2-positive subtypes (16% and 17%, respectively; P < 0...
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38637144/absorbed-dose-response-relationship-in-patients-with-gastroenteropancreatic-neuroendocrine-tumors-treated-with-177-lu-lu-dotatate-one-step-closer-to-personalized-medicine
#36
JOURNAL ARTICLE
Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès, Pierre-Olivier Kotzki, Emmanuel Deshayes
[177 Lu]Lu-DOTATATE has been approved for progressive and inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that overexpress somatostatin receptors. The absorbed doses by limiting organs and tumors can be quantified by serial postinfusion scintigraphy measurements of the γ-emissions from 177 Lu. The objective of this work was to explore how postinfusion [177 Lu]Lu-DOTATATE dosimetry could influence clinical management by predicting treatment efficacy (tumor shrinkage and survival) and toxicity...
April 18, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38637143/recip-1-0-predicts-progression-free-survival-after-177-lu-lu-psma-radiopharmaceutical-therapy-in-patients-with-metastatic-castration-resistant-prostate-cancer
#37
JOURNAL ARTICLE
Andrei Gafita, Loic Djaileb, Isabel Rauscher, Wolfgang P Fendler, Boris Hadaschik, Steven P Rowe, Ken Herrmann, Lilja B Solnes, Jeremie Calais, Matthew B Rettig, Manuel Weber, Andrea Farolfi, Matthias R Benz, Matthias Eiber
Response Evaluation Criteria in Prostate-Specific Membrane Antigen Imaging (RECIP) 1.0 is an evidence-based framework to evaluate therapeutic efficacy in metastatic prostate cancer using prostate-specific membrane antigen (PSMA) PET/CT. This study aimed to evaluate the associations of interim PSMA PET/CT by RECIP 1.0 with short-term outcome after radiopharmaceutical treatment. Methods: This multicenter retrospective study included patients with metastatic castration-resistant prostate cancer who underwent [177 Lu]Lu-PSMA radiopharmaceutical therapy at 3 academic centers and received PSMA PET/CT at baseline and at 12 wk...
April 18, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38637142/safety-and-efficacy-of-para-aminohippurate-coinfusion-for-renal-protection-during-peptide-receptor-radiotherapy-in-patients-with-neuroendocrine-tumors
#38
JOURNAL ARTICLE
Alexandros Moraitis, Walter Jentzen, Pedro Fragoso Costa, David Kersting, Stephan Himmen, Marta Coelho, Marian Meckel, Cees J A van Echteld, Wolfgang P Fendler, Ken Herrmann, Miriam Sraieb
Para -aminohippurate, also known as p -aminohippuric acid (PAH), is used clinically to measure effective renal plasma flow. Preclinically, it was shown to reduce 177 Lu-DOTATOC uptake in the kidneys while improving bioavailability compared with amino acid (AA) coinfusion. We report the safety and efficacy of PAH coinfusion during peptide receptor radiotherapy in patients with neuroendocrine tumors. Methods: Twelve patients with metastatic or unresectable gastroenteropancreatic neuroendocrine tumors received 177 Lu-DOTATOC in 33 treatment cycles...
April 18, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38637141/a-deep-learning-based-partial-volume-correction-method-for-quantitative-177-lu-spect-ct-imaging
#39
JOURNAL ARTICLE
Julian Leube, Johan Gustafsson, Michael Lassmann, Maikol Salas-Ramirez, Johannes Tran-Gia
With the development of new radiopharmaceutical therapies, quantitative SPECT/CT has progressively emerged as a crucial tool for dosimetry. One major obstacle of SPECT is its poor resolution, which results in blurring of the activity distribution. Especially for small objects, this so-called partial-volume effect limits the accuracy of activity quantification. Numerous methods for partial-volume correction (PVC) have been proposed, but most methods have the disadvantage of assuming a spatially invariant resolution of the imaging system, which does not hold for SPECT...
April 18, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38637140/a-systematic-review-on-the-diagnostic-value-of-fibroblast-activation-protein-inhibitor-pet-ct-in-genitourinary-cancers
#40
JOURNAL ARTICLE
Marinus J Hagens, Pim J van Leeuwen, Maurits Wondergem, Thierry N Boellaard, Francesco Sanguedolce, Daniela E Oprea-Lager, Axel Bex, André N Vis, Henk G van der Poel, Laura S Mertens
In contemporary oncologic diagnostics, molecular imaging modalities are pivotal for precise local and metastatic staging. Recent studies identified fibroblast activation protein as a promising target for molecular imaging across various malignancies. Therefore, we aimed to systematically evaluate the current literature on the utility of fibroblast activation protein inhibitor (FAPI) PET/CT for staging patients with genitourinary malignancies. Methods: A systematic Embase and Medline search was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) process, on August 1, 2023...
April 18, 2024: Journal of Nuclear Medicine
journal
journal
20164
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.